The trial will include patients with non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers.
With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.
In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...
HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...
NEW YORK – BlossomHill Therapeutics on Wednesday said it has begun treating lung cancer patients with EGFR- or HER2-mutated tumors with its OMNI-EGFR inhibitor BH-30643 in a Phase I/II trial. The ...
NEW YORK – Axovia Therapeutics and Viralgen on Wednesday said they have entered into a partnership to advance development and manufacturing for AXV-101, a gene therapy designed to treat retinal ...
The Shanghai-based firm will test the gene therapy candidate in patients between 4 and 9 years old with Duchenne muscular dystrophy.
The firm said it has received positive feedback from the FDA on the design of a Phase III trial of ELI-002 in KRAS-mutant pancreatic cancer.
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...
Doctors and patient advocates supporting pretreatment testing at times challenged FDA and other experts who aren't swayed by available evidence.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback